Krystal Biotech Announces FDA RMAT Designation for KB103 Gene Therapy and Plans to Initiate Pivotal Phase 3 Trial in 2026

Recently, Krystal Biotech announced that its gene therapy KB103 in Phase 2Clinical Trialachieved positive results in the treatment of dystrophic epidermolysis bullosa (DEB). The therapy also receivedFDAGrantedRegenerative MedicineRegenerative Medicine Advanced Therapy (RMAT) Designation. The RMAT designation aims to expedite regenerative medicine products (includingGene Therapyproducts) development and approval.

DEB is a rare chronicGeneticsIn this genetic disorder, mutations in the gene encoding type VII collagen (COL7) result in a deficiency of collagen in the skin, leading to separation of the epidermis from the dermis. Patients’ skin is abnormally sensitive and fragile; minor friction or trauma can cause blistering or sloughing, inflicting unbearable pain. Currently, there are no approved treatments for this disease.

KB103 is a replication-defective, non-integrating virusVector, leveraging Krystal Biotech’s STAR-D platform for engineered production, enables the direct delivery of a fully functional human COL7A1 gene to both dividing and non-dividing skin cells in patients. HSV-1 and other virusesVectorIn comparison, it can more effectively penetrate skin cells. Meanwhile, HSV-1 can accommodate large volumes and high quantities of genes, and due to its low immunogenicity, it has become a suitable vector for the direct and repeated delivery of transgenes to skin cells.Carrier。

In Phase 2 of KB103Clinical Trial(GEM-2) Among six patients with skin injuries, five achieved 100% wound closure following treatment with KB103. The mean time to achieve 100% wound closure in KB103-treated wounds was 23 days. Except for one case of chronic wound, all other wounds treated with KB103 maintained 100% closure for 90 days.

Dr. Peter Marinkovich, Associate Professor of Dermatology at Stanford University and Principal Investigator of the GEM study, noted that there is an urgent need to provide new treatments for patients with epidermolysis bullosa (EB), particularly simple and painless therapies to alleviate their suffering. The positive results from the Phase 1 and 2 clinical trials of KB103 have offered new hope for the treatment of epidermolysis bullosa. The company plans to initiate a pivotal Phase 3 trial by the end of this year.Clinical Trial。(BioValleyBioon.com）